BioNexus Gene Lab Corp. Operating Expenses
BioNexus Gene Lab Corp. (BGLC) reported Operating Expenses of $416.38 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- BioNexus Gene Lab Corp. operating expenses for the quarter ending 2026-06-30 was $416.38K, a 64.97% decline year-over-year.
- BioNexus Gene Lab Corp. operating expenses for the quarter ending 2026-03-31 was $597.39K, a 43.29% decline year-over-year.
- BioNexus Gene Lab Corp. operating expenses for the quarter ending 2025-12-31 was $1.05M, a 24.86% decline year-over-year.
- BioNexus Gene Lab Corp. operating expenses for the quarter ending 2025-09-30 was $1.19M, a 44.22% decline year-over-year.
- BioNexus Gene Lab Corp. operating expenses for fiscal 2025 was $4.48M, a 9.18% decline from fiscal 2024.
- BioNexus Gene Lab Corp. operating expenses for fiscal 2024 was $4.94M.
- BioNexus Gene Lab Corp. operating expenses for fiscal 2023 was -$4.41M.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $416.38K 10-Q · filed 2026-08-14 | $1.01M 10-Q · filed 2026-08-14 | $2.07M derived: sum of 3 quarters · filed 2026-08-14 | $3.25M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $597.39K 10-Q · filed 2026-05-15 | $1.65M derived: sum of 2 quarters · filed 2026-05-15 | $2.84M derived: sum of 3 quarters · filed 2026-05-15 | $4.03M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $2.24M derived: sum of 2 quarters · filed 2026-04-14 | $3.43M derived: sum of 3 quarters · filed 2026-08-14 | $4.48M 10-K · filed 2026-04-14 | ||
| 2025-09-30 | $1.19M 10-Q · filed 2025-11-14 | $2.38M derived: sum of 2 quarters · filed 2026-08-14 | $3.43M 10-Q · filed 2025-11-14 | $4.83M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $1.19M 10-Q · filed 2026-08-14 | $2.24M 10-Q · filed 2026-08-14 | $3.64M derived: sum of 3 quarters · filed 2026-08-14 | $5.77M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $1.05M 10-Q · filed 2026-05-15 | -$1.05M 10-Q · filed 2025-05-15 | $2.45M derived: sum of 2 quarters · filed 2026-05-15 | $4.58M derived: sum of 3 quarters · filed 2026-05-15 | $5.34M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $3.53M derived: sum of 2 quarters · filed 2026-04-14 | $4.29M derived: sum of 3 quarters · filed 2026-04-14 | $4.94M 10-K · filed 2026-04-14 | -$4.94M 10-K · filed 2025-04-15 | |
| 2024-09-30 | $2.13M 10-Q · filed 2025-11-14 | $2.89M derived: sum of 2 quarters · filed 2025-11-14 | $3.54M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | $759.66K 10-Q · filed 2025-08-18 | $1.41M 10-Q · filed 2025-08-18 | ||||
| 2024-03-31 | -$645.91K 10-Q · filed 2025-05-15 | |||||
| 2023-12-31 | -$4.41M 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |